Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 2
1959 2
1960 1
1961 2
1962 2
1963 3
1964 2
1965 2
1967 1
1968 2
1971 2
1978 2
1981 1
1983 1
1984 1
1985 2
1986 3
1987 7
1988 3
1989 4
1990 7
1991 4
1992 4
1993 7
1994 4
1995 6
1996 7
1997 17
1998 7
1999 5
2000 17
2001 16
2002 21
2003 20
2004 14
2005 12
2006 5
2007 28
2008 27
2009 38
2010 28
2011 30
2012 26
2013 17
2014 20
2015 34
2016 17
2017 39
2018 33
2019 31
2020 35
2021 31
2022 39
2023 30
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

652 results

Results by year

Filters applied: . Clear all
Page 1
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. Strober B, et al. Among authors: foley p. J Am Acad Dermatol. 2023 Jan;88(1):40-51. doi: 10.1016/j.jaad.2022.08.061. Epub 2022 Sep 14. J Am Acad Dermatol. 2023. PMID: 36115523 Free article. Clinical Trial.
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I; IRONMAN Study Group. Kalra PR, et al. Among authors: foley pwx. Lancet. 2022 Dec 17;400(10369):2199-2209. doi: 10.1016/S0140-6736(22)02083-9. Epub 2022 Nov 5. Lancet. 2022. PMID: 36347265 Free article. Clinical Trial.
Clinical Management of Pain in Rodents.
Foley PL, Kendall LV, Turner PV. Foley PL, et al. Comp Med. 2019 Dec 1;69(6):468-489. doi: 10.30802/AALAS-CM-19-000048. Epub 2019 Dec 10. Comp Med. 2019. PMID: 31822323 Free PMC article. Review.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Blauvelt A, et al. Among authors: foley p. Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4. Lancet. 2017. PMID: 28478972 Clinical Trial.
Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics.
Yeoh SE, Osmanska J, Petrie MC, Brooksbank KJM, Clark AL, Docherty KF, Foley PWX, Guha K, Halliday CA, Jhund PS, Kalra PR, McKinley G, Lang NN, Lee MMY, McConnachie A, McDermott JJ, Platz E, Sartipy P, Seed A, Stanley B, Weir RAP, Welsh P, McMurray JJV, Campbell RT. Yeoh SE, et al. Among authors: foley pwx. Eur Heart J. 2023 Aug 14;44(31):2966-2977. doi: 10.1093/eurheartj/ehad341. Eur Heart J. 2023. PMID: 37210742 Free PMC article. Clinical Trial.
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S. Papp K, et al. Among authors: foley p. N Engl J Med. 2018 Oct 4;379(14):1313-1321. doi: 10.1056/NEJMoa1806382. Epub 2018 Sep 11. N Engl J Med. 2018. PMID: 30205746 Free article. Clinical Trial.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Gordon KB, et al. Among authors: foley p. Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7. Lancet. 2018. PMID: 30097359 Clinical Trial.
NeurHistAlert 27.
Stahnisch FW, Foley P. Stahnisch FW, et al. Among authors: foley p. J Hist Neurosci. 2024 Jan-Mar;33(1):95-110. doi: 10.1080/0964704X.2023.2261352. Epub 2024 Feb 7. J Hist Neurosci. 2024. PMID: 37906053 Review. No abstract available.
Class II malocclusion correction with Invisalign: Is it possible?
Patterson BD, Foley PF, Ueno H, Mason SA, Schneider PP, Kim KB. Patterson BD, et al. Among authors: foley pf. Am J Orthod Dentofacial Orthop. 2021 Jan;159(1):e41-e48. doi: 10.1016/j.ajodo.2020.08.016. Epub 2020 Nov 19. Am J Orthod Dentofacial Orthop. 2021. PMID: 33223374
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Reich K, et al. Among authors: foley p. J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057361 Free article. Clinical Trial.
652 results